Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Oncogene. 2021 Oct 4;40(46):6456–6468. doi: 10.1038/s41388-021-02035-6

Extended Data Fig. 6. Effect of Yap inhibitor Verteporfin (VP) on YAP and AKT expression and activation.

Extended Data Fig. 6

related to Fig. 4 and Fig. 2.

a, Protein expression in WT (pooled 573, 604, 2595, 3850 and 3853) and TKO (pooled 717, 719, 720, 7320) fibrosarcoma cells, treated with or without PDGF (500 ng/μl), high dose (5 μM) or low dose (1 μM) Verteporfin for 8 h. Representative of 3 or 4 independent experiments.

b,c, Quantification of p-YAP 127 (b) and YAP/ACTIN (c).

d-f, Quantification of p-AKT473 (d), AKT/ACTIN (e) and p-AKT473/AKT (f). In d, p<0.000001 for WT and TKO under PDGF stimulation only, p<0.000001 for WT and TKO plus VP 1 μM under PDGF stimulation, p=0.0014 for WT and WT plus VP 5 μM under PDGF stimulation, p=0.0036 for TKO and TKO plus VP 5 μM under PDGF stimulation. In f, p=0.000829 for WT and TKO under PDGF stimulation only, p<0.016803 for WT and TKO plus VP 1 μM under PDGF stimulation, p=0.0108 for WT and WT plus VP 5 μM under PDGF stimulation, p=0.0356 for TKO and TKO plus VP 5 μM under PDGF stimulation.

*p < 0.05, **p < 0.01, ***p < 0.001; data are presented as mean ± SEM. Statistical significance was determined by multiple t- test or two-tailed unpaired t-test.